FDA atezolizumab coverage for business development, investment, and market access teams
Earlier
High impact AnalysisJun 6, 2026
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
FDA · non-small cell lung cancer · 5 min
Dr. Sarah MitchellHigh impact NewsJun 2, 2026
FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy
FDA · muscle invasive bladder cancer · 7 min
Dr. Sarah MitchellMedium impact NewsMay 19, 2026
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
FDA · oncology · 3 min
Dr. Sarah MitchellHigh impact NewsApr 9, 2026
FDA Approves Tecentriq for Extensive-Stage Small Cell Lung Cancer
FDA · oncology · 4 min
Dr. Sarah MitchellPopular topics
- Drug Approvals 1,128 articles
- Clinical Trials 634 articles
- Regulatory Updates 687 articles
- FDA News 502 articles
- Press Releases 443 articles
- Oncology 443 articles
- Rare Diseases 141 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways